DOCSLIB.ORG

Disposition of T Oxic Drugs and Chemicals

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Disposition of T Oxic Drugs and Chemicals Disposition of Toxic Drugs and Chemicals in Man, Eleventh Edition Eleventh Edition in Man and Chemicals Drugs Toxic Disposition of The purpose of this work is to present in a single convenient source the current essential information on the disposition of the chemi- cals and drugs most frequently encountered in episodes of human poisoning. The data included relate to the body fluid concentrations of substances in normal or therapeutic situations, concentrations in fluids and tissues in instances of toxicity and the known metabolic fate of these substances in man. Brief mention is made of specific analytical procedures that are applicable to the determination of each substance and its active metabolites in biological specimens. It is expected that such information will be of particular interest and use to toxicologists, pharmacologists, clinical chemists and clinicians who have need either to conduct an analytical search for these materials in specimens of human origin or to interpret 30 Amberwood Parkway analytical data resulting from such a search. Ashland, OH 44805 by Randall C. Baselt, Ph.D. Former Director, Chemical Toxicology Institute Bookmasters Foster City, California HARD BOUND, 7” x 10”, 2500 pp., 2017 ISBN 978-0-692-77499-1 USA Reviewer Comments on the Tenth Edition “...equally useful for clinical scientists and poison information centers and others engaged in practice and research involving drugs.” Y. Caplan, J. Anal. Tox. “...continues to be an invaluable and essential resource for the forensic toxicologist and pathologist.” D. Fuller, SOFT ToxTalk “...has become an essential reference book in many laboratories that deal with clinical or forensic cases of poisoning.” M. Hastedt, For. Sci. Med. Path. “...provides a concise source of information important for the understanding of the clinical and forensic significance of various substances in the human body.” D.G. Barceloux, Clinical Toxicology “...continues on the fine tradition of resource that now POSTAGE includes over 1500 drugs and other poisons...” PLACE HERE O.H, Drummer, For. Sci. Int. ALSO AVAILABLE Drug Effects on Psychomotor Performance HARD BOUND, 7” x 10”, 475 pp., 2001 LIBRARY OF CONGRESS CONT. NO. 00-133235 ISBN 0-9626523-4-2 CONTENTS BOOK ORDER FORM Monographs devoted to each of the following substances are presented in alphabetical order. Every monograph includes detailed information as to Occurrence and Usage, Blood Concentrations, Metabolism and Excretion, Toxicity and Analysis of the substance. Complete literature citations are provided at the end. PLEASE SEND: Abacavir Arecoline Budesonide Chloroprocaine Deferoxamine EAPB Flocoumafen Hydroxychloroquine Loperamide p-MethoxyMA Nilotinib Phenazepam a-PVPP Sugammadex Tolterodine Abamectin Arformoterol Buflomedil Chloroquine Deflazacort Ebastine Flubromazepam Hydroxy-DIPT Lopinavir Methoxyphencyclidine Nilutamide Phenazopyridine Pyrantel Sulbactam Toluene Abiraterone acetate Argatroban Buformin Chlorothalonil Dehydroepiandrosterone EDB Flubromazolam Hydroxyurea Loprazolam Methoxyphenidine Nimesulide Phencyclidine Pyrazinamide Sulbutiamine Tolvaptan Abrin Argine Bufotenine Chlorothiazide Delapril Edoxaban Flucloxacillin Hydroxyzine Loratadine Methsuximide Nimodipine Phendimetrazine Pyrazolam Sulfadiazine Topiramate ...........COPIES: Disposition of Toxic Drugs and Acamprosate Aripiprazole Bumetanide Chlorphenesin Delavirdine Edrophonium Fluconazole Hyoscyamine Lorazepam Methylaminorex Nintedanib Phenelzine Pyridostigmine Sulfadoxine Topotecan Acarbose Armodafinil Buphedrone Carbamate Delorazepam EDTA Flucytosine Hypoglycin A Lorcaserin 4-Methylamphetamine Nisoldipine Phenethylamine Pyrilamine Sulfamethoxazole Toremifene Acebutolol Arsenic Bupivacaine Chlorpheniramine Deltamethrin Efavirenz Fludarabine Ibandronate Lormetazepam Methyl bromide Nitisone Phenformin Pyrimethamine Sulfasalazine Torsemide Chemicals in Man at $349.50 each. Aceclofenac Artemether Bupranolol Chlorphentermine Demeclocycline Eflornithine Flumazenil Ibogaine Lornoxicam Methyl t-butyl ether Nitrazepam Phenibut Pyritinol Sulfinpyrazone Trabectedin Acenocoumarol Artemisinin Buprenorphine Chlorproguanil Demeton-S-methyl Eletriptan Flunarizine Ibotenic acid Losartan Methyl n-butyl ketone Nitrendipine Pheniramine Pyronaridine Sulfur mustard Tramadol Acephate Artesunate Bupropion Chlorpromazine 23-epi-26-Deoxyactein Eliglustat Flunisolide Ibrutinib Lovastatin Methyl chloride Nitrite Phenmetrazine Pyrovalerone Sulfuryl fluoride Trametinib Acepromazine Articaine Buspirone Chlorpropamide Desflurane Eluxadoline Flunitrazepam Ibuprofen Loxapine Methyldigoxin Nitrobenzene Phenobarbital Quazepam Sulindac Trandolapril ...........COPIES: Drug Effects on Psychomotor Acetaldehyde Asenapine Busulfan Chlorprothixene Desipramine Elvitegravir Fluoride Ibutilide Loxoprofen Methyldopa Nitroethane Phenol Quercetin Sulpiride Tranexamic acid Acetaminophen Aspartame Butabarbital Chlorpyrifos Desloratadine Embutramide Fluoroacetate Idarubicin LSD Methylene blue Nitrofurantoin Phenolphthalein Quetiapine Sultopride Tranylcypromine Acetamiprid Atazanavir 1,3-Butadiene Chlorpyrifos methyl Desmopressin Emedastine Fluorocarbons Idebenone Lubiprostone Methylephedrine Nitroglycerin Phenothrin Quinalphos Sumatriptan Trazodone Performance at $109.00 each. Acetazolamide Atenolol Butalbital Chlorthalidone Desoxypipradrol Emetine Fluorophenmetrazine Idelalisib Lumefantrine Methylergonovine Nitromethane Phenprocoumon Quinapril Sunitinib Trenbolone Acetone Atomoxetine Butane Chlorzoxazone Desvenlafaxine Empagliflozin 5-Fluorouracil Ifosfamide Lumiracoxib Methylethcathinone Nitroprusside Phenpropabamate Quinidine Suvorexant Trepostinil Acetonitrile Atorvastatin n-Butanol Chromium Dexamethasone Emtricitabine Fluoxetine Ilaprazole Lupanine Methyl ethyl ketone Nitrous oxide Phentermine Quinine Synephrine Tretinoin Acetylcarnitine Atosiban Butaperazine Cibenzoline Dexfenfluramine Enalapril Fluoxymesterone ILGF-1 Lurasidone Methylfentanyl Nizatidine Phenthoate Rabeprazole 2,4,5-T Triamcinolone A $16.00 shipping and handling charge will be added for Acetylcysteine Atovaquone Butenafine Ciclesonide Dexibuprofen Endosulfan Flupentixol Iloperidone Luteinizing hormone Methylformate Noopept Phenylbutazone Ractopamine Tabun Triamterene Acetylene Atractyloside Butethal Cidofovir Dexketoprofen Endrin Fluphenazine Iloprost Lysergamide Methyl Iodide Norandrostenediol p-Phenylenediamine Raloxifene Tacrine Triazolam Acetylfentanyl Atracurium Butorphanol Ciguatoxin Dexlansoprazole Enflurane Flupirtine Imatinib Macitentan Methylmethcathinone Nordazepam Phenylephrine Raltegravir Tacrolimus Trichloroethane the first copy, plus $5.00 for each additional copy. Orders Acetylmethadol Atrazine 2-Butoxyethanol Cilnidipine Dexmedetomidine Enfuvirtide Flurazepam Imidacloprid Magnesium Methylnaltrexone br Norfloxacin Phenylpropanolamine Raltitrexed Tadalafil Trichloroethylene Acetylsalicylic acid Atropine Butriptyline Cilostazol Dexmethylphenidate Enobosarm Flurbiprofen Imipenem Malathion Methylone Nortriptyline Phenytoin Ramelteon Talinolol Triclabendazole for 5 or more books will be billed at the actual shipping Acitretin Avanafil Butyl nitrite Cimetidine Dextromethorphan Enoxaparin Flutamide Imipramine Mancozeb Methyl parathion Noscapine Pholcodine Ramipril Tamoxifen Triclopyr Aclidinium Axitinib Butylone Cinacalcet Dextromoramide Entacapone Fluticasone furoate Inamrinone Maneb Methylphenethylamine Nystatin Pholedrine Ramosetron Tamsulosin Triclosan Aconitine Azacitidine N-Butylscopolamine Cinnarizine Dezocine Enzalutamide Fluticasone prop. 25I-NBOMe Manganese Methylphenidate Obidoxime chloride Phorate Ranitidine Tapentadol Trientine cost. International orders will be shipped via Priority Acrivastine Azathioprine Butyrfentanyl Ciprofloxacin Diacerein Eperisone Fluvastatin Indacaterol Manidipine Methylprednisolone Ochratoxin A Phosalone Ranolazine Tasimelteon Trifluoperazine Acrolein Azelastine Cabazitaxel Cisapride Diazepam Ephedrine Fluvoxamine Indapamide MAPB Methylpyrrolidone Octreotide Phosphamidon Rasagiline Taurine Triflusal Acrylamide Azelnidipine Cabergoline Cisatracurium Diazinon Epinastine Folpet Indinavir Maprotiline Methyl salicylate Ofloxacin Phosphate Reboxetine Taxine Trihexyphenidyl International for $45.00, plus $10.00 for each additional Acrylonitrile Azide Cabozantinib Cisplatin Dibenzepine Epinephrine Fomepizole Indomethacin Maraviroc Methyltestosterone Olanzapine Phosphine Regorafenib Tazobactam Trimebutine Actinomycin D Azilsartan Cadmium Citalopram Dibucaine Epirubicin Fondaparinux Infliximab Mazindol a-Methyltryptamine Olaparib Physostigmine Remifentanil 1,2,3-TCP Trimecaine copy. Acyclovir Azinphos-methyl Caffeine Citicoline Dicamba Eplerenone Formaldehyde Insulin MBDB Methysergide Oleandrin Picamilon Repaglinide TDI Trimeprazine Adalimumab Azithromycin Calcium carbimide Cladribine p-Dichlorobenzene EPN Formestane Iodine MCPA Metoclopramide Olmesartan Picloram Reserpine Tebuconazole Trimetazidine Adefovir dipivoxil Aztreonam Camazepam Clarithromycin Dichloroethane Epoetin alfa Formic acid Iodixanol MCPMT Metolazone Olodaterol Picosulfate sodium Resorcinol Tedizolid Trimethoprim Adenosine Baclofen Camphor Clavulanic acid Dichloromethane Epoetin beta Formoterol 4-Iodo-DMPEA MDA Metoprolol Olopatadine Pilocarpine Resveratrol Tegafur Trimipramine All orders must be paid in advance. Purchase orders can- Adrafinil Balsalazide Canagliflozin Clemastine Dichlorophen Epoetin b-MPEG Fosamprenavir Iohexol 4,4’-MDA Metrifonate Olsalazine Pilsicainide Retigabine Teicoplanin Trinitrotoluene
Load more

Recommended publications
  • XTANDI® (Enzalutamide): a Treatment Option for Castration-Resistant Prostate Cancer (CRPC)
    XTANDI® (enzalutamide): A Treatment Option for Castration-Resistant Prostate Cancer (CRPC) XTANDI® (enzalutamide) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with castration-resistant prostate cancer (CRPC).1 XTANDI is the first and only oral medication FDA-approved for both non-metastatic and metastatic CRPC.1 ABOUT THE ASTELLAS/PFIZER HOW XTANDI WORKS COLLABORATION Astellas and Pfizer jointly XTANDI is indicated for the treatment of CRPC, commercialize XTANDI which is defined as disease progression on in the United States. androgen deprivation therapy (luteinizing hormone-releasing hormone (LHRH) therapy Astellas has responsibility or prior bilateral orchiectomy).2 for manufacturing and all additional regulatory In prostate cancer, the androgen receptor (AR) is a key driver filings globally, as well as of progression.3 XTANDI is an AR inhibitor that is thought commercializing XTANDI to act on multiple steps of the androgen receptor signaling 1 outside the United States. pathway within the tumor cell based on in vitro studies. Select Safety Information Seizure occurred in 0.4% of patients receiving XTANDI in clinical studies. In a study of patients with predisposing factors for seizure, 2.2% of XTANDI-treated patients experienced a seizure. Patients in the study had one or more of the following pre-disposing factors: use of medications that may lower the seizure threshold; history of traumatic brain or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer’s disease, meningioma, or leptomeningeal disease from prostate cancer, unexplained loss of consciousness within the last 12 months, history of seizure, presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection.
    [Show full text]
  • The 2021 List of Pharmacological Classes of Doping Agents and Doping Methods
    BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 1 von 23 The 2021 list of pharmacological classes of doping agents and doping methods www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 2 von 23 www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 3 von 23 THE 2021 PROHIBITED LIST WORLD ANTI-DOPING CODE DATE OF ENTRY INTO FORCE 1 January 2021 Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 1 January 2021. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In- Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List.
    [Show full text]
  • Yerevan State Medical University After M. Heratsi
    YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY HANDOUT for the 3-rd-year pharmacy students (part 2) YEREVAN 2017 Analgesic Agents Agents that decrease pain are referred to as analgesics or as analgesics. Pain relieving agents are also called antinociceptives. An analgesic may be defined as a drug bringing about insensibility to pain without loss of consciousness. Pain has been classified into the following types: physiological, inflammatory, and neuropathic. Clearly, these all require different approaches to pain management. The three major classes of drugs used to manage pain are opioids, nonsteroidal anti-inflammatory agents, and non opioids with the central analgetic activity. Narcotic analgetics The prototype of opioids is Morphine. Morphine is obtained from opium, which is the partly dried latex from incised unripe capsules of Papaver somniferum. The opium contains a complex mixture of over 20 alkaloids. Two basic types of structures are recognized among the opium alkaloids, the phenanthrene (morphine) type and the benzylisoquinoline (papaverine) type (see structures), of which morphine, codeine, noscapine (narcotine), and papaverine are therapeutically the most important. The principle alkaloid in the mixture, and the one responsible for analgesic activity, is morphine. Morphine is an extremely complex molecule. In view of establish the structure a complicated molecule was to degrade the: compound into simpler molecules that were already known and could be identified. For example, the degradation of morphine with strong base produced methylamine, which established that there was an N-CH3 fragment in the molecule.
    [Show full text]
  • Crowdsourcing Analysis of Off-Label Intervention Usage in Amyotrophic Lateral Sclersosis
    CROWDSOURCING ANALYSIS OF OFF-LABEL INTERVENTION USAGE IN AMYOTROPHIC LATERAL SCLERSOSIS A Thesis Presented to The Academic Faculty by Benjamin I. Mertens In Partial Fulfillment of the Requirements for the Degree B.S. in Biomedical Engineering with the Research Option in the Wallace H. Coulter School of Biomedical Engineering Georgia Institute of Technology Spring 2017 1 ACKNOWLEDGEMENTS I would like to thank my research advisor, Dr. Cassie Mitchell, first and foremost, for helping me through this long process of research, analysis, writing this thesis and the corresponding article to be submitted for peer-reviewed journal publication. There is no way I could have done this, or written it as eloquently without her. Next, I would like to acknowledge Grant Coan, Gloria Bowen, and Nathan Neuhart for all helping me on the road to writing this paper. Lastly, I would like to thank Dr. Lena Ting for her consultation as the faculty reader. 2 TABLE OF CONTENTS Page ACKNOWLEDGEMENTS 2 LIST OF TABLES 4 LIST OF FIGURES 5 LIST OF ABBREVIATIONS 6 SUMMARY 7 CHAPTERS 1 Philosophy 9 2 Crowdsourced Off-label Medications to Extend ALS Disease Duration 12 Introduction 12 Methodology 15 Results 18 Discussion 25 Tables 33 Figures 38 APPENDIX A: All Table 2 Appearance in Patients and Visits 44 APPENDIX B: All Table 3 Appearance in Patients and Visits 114 REFERENCES 129 3 LIST OF TABLES Page Table 1: Database Overview 33 Table 2: Ontology of Individual Medications 34 Table 3: Ontology of Intervention Groups 36 4 LIST OF FIGURES Page Figure 1: Relational circle
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Drug Testing Program
    DRUG TESTING PROGRAM Copyright © 2021 CrossFit, LLC. All Rights Reserved. CrossFit is a registered trademark ® of CrossFit, LLC. 2021 DRUG TESTING PROGRAM 2021 DRUG TESTING CONTENTS 1. DRUG-FREE COMPETITION 2. ATHLETE CONSENT 3. DRUG TESTING 4. IN-COMPETITION/OUT-OF-COMPETITION DRUG TESTING 5. REGISTERED ATHLETE TESTING POOL (OUT-OF-COMPETITION DRUG TESTING) 6. REMOVAL FROM TESTING POOL/RETIREMENT 6A. REMOVAL FROM TESTING POOL/WATCH LIST 7. TESTING POOL REQUIREMENTS FOLLOWING A SANCTION 8. DRUG TEST NOTIFICATION AND ADMINISTRATION 9. SPECIMEN ANALYSIS 10. REPORTING RESULTS 11. DRUG TESTING POLICY VIOLATIONS 12. ENFORCEMENT/SANCTIONS 13. APPEALS PROCESS 14. LEADERBOARD DISPLAY 15. EDUCATION 16. DIETARY SUPPLEMENTS 17. TRANSGENDER POLICY 18. THERAPEUTIC USE EXEMPTION APPENDIX A: 2020-2021 CROSSFIT BANNED SUBSTANCE CLASSES APPENDIX B: CROSSFIT URINE TESTING PROCEDURES - (IN-COMPETITION) APPENDIX C: TUE APPLICATION REQUIREMENTS Drug Testing Policy V4 Copyright © 2021 CrossFit, LLC. All Rights Reserved. CrossFit is a registered trademark ® of CrossFit, LLC. [ 2 ] 2021 DRUG TESTING PROGRAM 2021 DRUG TESTING 1. DRUG-FREE COMPETITION As the world’s definitive test of fitness, CrossFit Games competitions stand not only as testaments to the athletes who compete but to the training methodologies they use. In this arena, a true and honest comparison of training practices and athletic capacity is impossible without a level playing field. Therefore, the use of banned performance-enhancing substances is prohibited. Even the legal use of banned substances, such as physician-prescribed hormone replacement therapy or some over-the-counter performance-enhancing supplements, has the potential to compromise the integrity of the competition and must be disallowed. With the health, safety, and welfare of the athletes, and the integrity of our sport as top priorities, CrossFit, LLC has adopted the following Drug Testing Policy to ensure the validity of the results achieved in competition.
    [Show full text]
  • Clinical Efficacy of Enzalutamide Vs Bicalutamide Combined with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sens
    Henry Ford Health System Henry Ford Health System Scholarly Commons Hematology Oncology Articles Hematology-Oncology 1-4-2021 Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone- Sensitive Prostate Cancer: A Randomized Clinical Trial Ulka N. Vaishampayan Lance K. Heilbrun Paul Monk Sheela Tejwani Guru Sonpavde See next page for additional authors Follow this and additional works at: https://scholarlycommons.henryford.com/ hematologyoncology_articles Authors Ulka N. Vaishampayan, Lance K. Heilbrun, Paul Monk, Sheela Tejwani, Guru Sonpavde, Clara Hwang, Daryn Smith, Pallavi Jasti, Kimberlee Dobson, Brenda Dickow, Elisabeth I. Heath, Louie Semaan, Michael L. Cher, Joseph A. Fontana, and Sreenivasa Chinni Original Investigation | Oncology Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer A Randomized Clinical Trial Ulka N. Vaishampayan, MD; Lance K. Heilbrun, PhD; Paul Monk III, MD; Sheela Tejwani, MD; Guru Sonpavde, MD; Clara Hwang, MD; Daryn Smith, MS; Pallavi Jasti, MD; Kimberlee Dobson, BS; Brenda Dickow, RN; Elisabeth I. Heath, MD; Louie Semaan, BS; Michael L. Cher, MD; Joseph A. Fontana, MD; Sreenivasa Chinni, PhD Abstract Key Points Question Is enzalutamide combined IMPORTANCE Black patients have been underrepresented in prospective clinical trials of advanced with androgen deprivation therapy prostate cancer. This study evaluated the efficacy of enzalutamide compared with bicalutamide, with associated with better outcomes than planned subset analysis of Black patients with metastatic hormone-sensitive prostate cancer treatment with bicalutamide in Black (mHSPC), which is a disease state responsive to androgen deprivation therapy (ADT). men with metastatic hormone-sensitive prostate cancer (mHSPC)? OBJECTIVE To compare the efficacy of enzalutamide vs bicalutamide in combination with ADT in men with mHSPC, with a subset analysis of Black patients.
    [Show full text]
  • AVMA Guidelines for the Depopulation of Animals: 2019 Edition
    AVMA Guidelines for the Depopulation of Animals: 2019 Edition Members of the Panel on Animal Depopulation Steven Leary, DVM, DACLAM (Chair); Fidelis Pharmaceuticals, High Ridge, Missouri Raymond Anthony, PhD (Ethicist); University of Alaska Anchorage, Anchorage, Alaska Sharon Gwaltney-Brant, DVM, PhD, DABVT, DABT (Lead, Companion Animals Working Group); Veterinary Information Network, Mahomet, Illinois Samuel Cartner, DVM, PhD, DACLAM (Lead, Laboratory Animals Working Group); University of Alabama at Birmingham, Birmingham, Alabama Renee Dewell, DVM, MS (Lead, Bovine Working Group); Iowa State University, Ames, Iowa Patrick Webb, DVM (Lead, Swine Working Group); National Pork Board, Des Moines, Iowa Paul J. Plummer, DVM, DACVIM-LA (Lead, Small Ruminant Working Group); Iowa State University, Ames, Iowa Donald E. Hoenig, VMD (Lead, Poultry Working Group); American Humane Association, Belfast, Maine William Moyer, DVM, DACVSMR (Lead, Equine Working Group); Texas A&M University College of Veterinary Medicine, Billings, Montana Stephen A. Smith, DVM, PhD (Lead, Aquatics Working Group); Virginia-Maryland College of Veterinary Medicine, Blacksburg, Virginia Andrea Goodnight, DVM (Lead, Zoo and Wildlife Working Group); The Living Desert Zoo and Gardens, Palm Desert, California P. Gary Egrie, VMD (nonvoting observing member); USDA APHIS Veterinary Services, Riverdale, Maryland Axel Wolff, DVM, MS (nonvoting observing member); Office of Laboratory Animal Welfare (OLAW), Bethesda, Maryland AVMA Staff Consultants Cia L. Johnson, DVM, MS, MSc; Director, Animal Welfare Division Emily Patterson-Kane, PhD; Animal Welfare Scientist, Animal Welfare Division The following individuals contributed substantively through their participation in the Panel’s Working Groups, and their assistance is sincerely appreciated. Companion Animals—Yvonne Bellay, DVM, MS; Allan Drusys, DVM, MVPHMgt; William Folger, DVM, MS, DABVP; Stephanie Janeczko, DVM, MS, DABVP, CAWA; Ellie Karlsson, DVM, DACLAM; Michael R.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • LIGANDROL Comprometimento Ósseo
    Apresenta ação anabólica com poucos efeitos androgênicos e virilizantes Auxilia no tratamento de condições onde há perda de massa muscular e LIGANDROL comprometimento ósseo Promove a hipertrofia e aumenta a força muscular O QUE É? RA especialmente pelos ligantes exógenos, como os esteróides anabolizantes androgênicos (EAA), pode estar envolvida com o O ligandrol, também conhecido como anabolicum ou LGD- desenvolvimento de patologias na próstata, coração e fígado. Isto 4033, é caracterizado como um modulador seletivo do receptor porque, o receptor RA está expresso em diferentes tecidos, o que de androgênio (SARM) de estrutura não esteroidal que atua de de certa forma limita o uso terapêutico dos EAA em condições forma seletiva sobre os tecidos que expressam os receptores mais específicas como sarcopenia, caquexia associada à doenças androgênicos (RA). Por sua especificidade e alta afinidade ao como câncer, osteoporose e hipogonadismo. RA, tem sido demonstrado que o ligandrol apresenta atividade anabólica no músculo e anti – reabsortiva e anabólica no tecido Com o intuito de contornar possíveis limitações que resultam da ósseo, ao passo que apresenta efeitos androgênicos mínimos ativação global dos RA, os moduladores seletivos de receptores sobre próstata, couro cabeludo e pele. 1 androgênicos, também conhecidos como SARMs, do inglês Selective Androgen Receptor Modulators, tem sido objeto de Os SARMs como o ligandrol e ostarine, têm sido avaliados como estudo uma vez que parecem ativar os RA de maneira específica uma alternativa eficaz e segura para o tratamento de perda e seletiva em determinados tecidos, reduzindo também a de massa muscular associada ao envelhecimento e a outras ocorrência de efeitos colaterais indesejados.
    [Show full text]
  • Rodenticides Snail Baits
    SPRING/SUMMER 2018 ISSUE 2018 CPD COURSES Key Areas Covered (six hours of CPD) • Case histories for potential poisons cases • Decontamination for poisons cases • Toxicology information resources • Common or tricky poisonings in cats and dogs Cost and Bookings Standard fee: £295 + VAT Early bird fee: £250 + VAT* Each delegate will receive course notes and a CPD certificate (equates to 6 hours CPD training). Lunch and refreshments are provided. Bookings: To reserve a place, please visit the link below and Welcome download the booking form. https://vpisglobal.com/class- Welcome to the Spring/Summer edition of Toxic Times. based-courses-2018/ Date Location Now that we can put thoughts of ice, snow and travel chaos behind us, it’s time to look ahead to the warmer months, which for many, means May 24th Liverpool gardening and for others, dieting. June 8th Winchester In the garden, we’ll discuss slug bait and Our Key Points to Preventing Poisoning July 19th Glasgow how it is vital that it be kept away from is a reminder and aid to keep our pets safe September 13th London pets and we’ll also look at xylitol, the sugar in the home and garden, and although replacement, and how it too must be kept mostly common sense, is worth reiterating. October 18th Exeter securely away from animals. November 29th Birmingham Finally, the regular update of forthcoming The less commonly seen rodenticide, CPD courses, which this year are proving alphachloralose is also discussed. extremely popular- possibly due in part * Early bird discount applies to bookings made up to 8 weeks prior to the course Case Corner highlights some recent to the provision of homemade cakes.
    [Show full text]
  • Alphachloralose Product-Type 14 (Rodenticide)
    CA-May08-Doc.3.1a WORKING DOCUMENT: DOES NOT NECESSARILY REPRESENT THE VIEWS OF THE COMMISSION Directive 98/8/EC concerning the placing biocidal products on the market Inclusion of active substances in Annex I or IA to Directive 98/8/EC Assessment Report Alphachloralose Product-type 14 (rodenticide) 30 May 2008 Annex I - PT Alphachloralose (PT 14) Assessment report Finalised in the Standing Committee on Biocidal Products at its meeting on 30 May 2008 in view of its inclusion in Annex I to Directive 98/8/EC CONTENTS 1. STATEMENT OF SUBJECT MATTER AND PURPOSE .................................. 4 1.1. Procedure followed.......................................................................................... 4 1.2. Purpose of the assessment report...................................................................5 1.3. Overall conclusion in the context of Directive 98/8/EC ...............................5 2. OVERALL SUMMARY AND CONCLUSIONS...................................................6 2.1. Presentation of the Active Substance ............................................................6 2.1.1. Identity, Physico-Chemical Properties & Methods of Analysis.......6 2.1.2. Intended Uses and Efficacy ...............................................................7 2.1.3. Classification and Labelling ..............................................................8 2.2. Summary of the Risk Assessment................................................................10 2.2.1. Human Health Risk Assessment......................................................10
    [Show full text]